<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="591">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358003</url>
  </required_header>
  <id_info>
    <org_study_id>MH-007/B</org_study_id>
    <nct_id>NCT04358003</nct_id>
  </id_info>
  <brief_title>Plasma Adsorption in Patients With Confirmed COVID-19</brief_title>
  <official_title>Plasma Adsorption in Patients With Confirmed COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marker Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marker Therapeutics AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol
      to reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients
      admitted to the ICU.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 27, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sequential Organ Failure Assessment [SOFA] scores</measure>
    <time_frame>Day 28</time_frame>
    <description>Scale of 0-24 with a higher number indicating a worse outcome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Plasma Adsorption Cartridge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Plasma Adsorption Cartridge</intervention_name>
    <description>Subjects will receive one treatment per day with the D2000 Cartridge for up to 4 hours (treatment cycle) for up to seven (7) days. Treatment may extend beyond 7 days, up to 14 days total, if deemed necessary and useful by the principal investigator (PI). Additional cartridges may be used, if needed, to achieve the maximum daily treatment duration of 4 hours.</description>
    <arm_group_label>Plasma Adsorption Cartridge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Admitted to ICU

          -  Diagnosis of SARS-CoV-2 with any one of the following conditions:

               1. Early acute lung injury (ALI)/early acute respiratory distress syndrome (ARDS);
                  or

               2. Severe disease, defined as:

                    1. dyspnea,

                    2. respiratory frequency ≥ 30/min

                    3. blood oxygen saturation ≤ 93%

                    4. partial pressure of arterial oxygen to fraction of inspired oxygen ratio &lt;
                       300, and/or

                    5. lung infiltrates &gt; 50% within 24 to 48 hours; or

               3. Life-threatening disease, defined as:

                    1. respiratory failure,

                    2. septic shock, and/or

                    3. multiple organ dysfunction or failure.

          -  Patient fact sheet is provided to the subject.

          -  Subject or legal representative is able and willing to give informed consent. If
             authorized by the IRB, emergent plasma adsorption with the D2000 cartridge may be
             initiated prior to consent.

        Exclusion Criteria:

          -  Treatment limitation or a do not attempt to resuscitate in place

          -  Pregnancy

          -  Significant or uncontrolled bleeding

          -  In the opinion of the investigator, any other condition that precludes plasma
             adsorption with the D2000
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eeke Romo, MD</last_name>
    <phone>1-877-339-4228</phone>
    <email>eekeromo@cox.net</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

